Nanjing Zhihe Pharmaceutical Technology Co. Ltd. has described nucleotide derivatives acting as prodrugs reported to be useful for the treatment of viral infections.
In its first markup of the 118th Congress May 2, the Senate Health, Education, Labor and Pensions (HELP) Committee, under the new leadership of Sen. Bernie Sanders (I-Vt.), devolved into a brief mutiny of sorts as the committee members started to take up four bipartisan bills aimed at taming prescription drug prices.
With its sights set on a series A and an IPO following a £3.5 million (US$4.4 million) investment round in 2021, Scottish biotech ILC Therapeutics Ltd. is hoping to make waves with a sublingual interferon antiviral to treat COVID-19. The USP for the company’s lead, Alfacyte, is the fact that it’s an artificial version of interferon, so it has less of a propensity to cause the flu-like symptoms that can come from treatment with natural kinds, which hike levels of cytokines and interleukins. As a hybrid interferon that is composed of interferon alpha-10 and interferon alpha-12, Alfacyte is “up to 10,000 times less likely” to cause adverse effects, according to ILC CEO Alan Walker.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bristol Myers Squibb, H. Lundbeck, Moderna, Otsuka, Pfizer, Rnaimmune, Senhwa.
Rnaimmune Inc., a nonwholly owned subsidiary of Sirnaomics Ltd., has received clearance from the FDA for its IND application to conduct a phase I trial for RV-1730, a SARS-CoV-2 vaccine booster candidate.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Arbutus, Atea, GSK, Hipra, In8bio, Invivyd, Myrtelle, Santhera, Stoke, Tarsier, Virios.
RSS
